Table 2 Proportion of patients with HIV-1 RNA <400 copies/mL and <50 copies/mL
Week | HIV-1 RNA <400 copies/mL, n/N (%) | Â | HIV-1 RNA <50 copies/mL, n/N (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | ITT: Observed | Â | ITT: M = F | Â | ITT: Observed | Â | ITT: M = F | ||||
| Â | Abacavir | PI | Â | Abacavir | PI | Â | Abacavir | PI | Â | Abacavir | PI |
Baseline | 52/52 (100) | 52/52 (100) | Â | 52/52 (100) | 52/52 (100) | Â | 42/52 (81) | 47/52 (90) | Â | 42/52 (81) | 47/52 (90) |
4 | 49/49 (100) | 44/45 (98) | Â | 49/52 (94) | 44/52 (85) | Â | 48/49 (98) | 43/45 (96) | Â | 48/52 (92) | 43/52 (83) |
8 | 39/42 (93) | 42/42 (100) | Â | 39/52 (75) | 42/52 (81) | Â | 38/42 (90) | 40/42 (95) | Â | 38/52 (73) | 40/52 (77) |
12 | 38/41 (93) | 40/40 (100) | Â | 38/52 (73) | 40/52 (77) | Â | 38/41 (93) | 39/40 (98) | Â | 38/52 (73) | 39/52 (75) |
20 | 38/41 (93) | 40/40 (100) | Â | 38/52 (73) | 40/52 (77) | Â | 32/41 (78) | 38/40 (95) | Â | 32/52 (62) | 38/52 (73) |
28 | 36/40 (90) | 40/40 (100) | Â | 36/52 (69) | 40/52 (77) | Â | 32/40 (80) | 39/40 (98) | Â | 32/52 (62) | 39/52 (75) |